How have HUMDF shares performed in 2024?

Hua Medicine (Shanghai)'s stock was trading at C$0.20 on January 1st, 2024. Since then, HUMDF stock has increased by 0.0% and is now trading at C$0.20. View the best growth stocks for 2024 here .

Are investors shorting Hua Medicine (Shanghai)?

Hua Medicine (Shanghai) saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 337,400 shares, a drop of 22.0% from the May 15th total of 432,400 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. View Hua Medicine (Shanghai)'s Short Interest .

How do I buy shares of Hua Medicine (Shanghai)?

Shares of HUMDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:HUMDF

Hua Medicine (Shanghai) (HUMDF) Stock Price, News & Analysis

→ Jeff Bezos & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad)

Free HUMDF Stock Alerts

C$0.20

0.00 (0.00%)

(As of 06/7/2023)

Compare

Today's Range: C$0.20
▼
C$0.20
50-Day Range: C$0.20
▼
C$0.20
52-Week Range: C$0.20
▼
C$0.20

Volume: 200 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Hua Medicine (Shanghai) alerts:

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

About Hua Medicine (Shanghai)

Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with insulin for late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease; and Fructokinase Inhibitor for Metabolic disease. The company was incorporated in 2011 and is based in Beijing, China.

HUMDF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HUMDF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive HUMDF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hua Medicine (Shanghai) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: OTCMKTS:HUMDF
CUSIP: N/A
CIK: N/A
Web: www.huamedicine.com
Phone: N/A
Fax: N/A
Employees: 177
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Li Chen Ph.D. (Age 61)
Founder, CEO & Executive Director
Comp: $1.11M
Mr. Chien Cheng Lin J.D. (Age 53)
Executive VP, Chief Strategy Officer & Executive Director
Comp: $846.22k
Dr. Fuxing Tang Ph.D. (Age 57)
CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA
Dr. Changhong Li Ph.D. (Age 55)
Chief Scientific Officer
Mr. Chengde Wang (Age 76)
Head of IR
Dr. Yi Zhang M.D. (Age 49)
Ph.D., Senior VP of Pharma Development, Chief Medical Officer China and Executive Director
Mr. Ying Xie M.B.A.
VP of Quality Assurance Division & Chief Quality Officer
Ms. Wing Yan Yuen FCIS (Age 54)
FCS, Company Secretary

Key Competitors

View All Competitors

HUMDF Stock Analysis - Frequently Asked Questions

How have HUMDF shares performed in 2024?: Hua Medicine (Shanghai)'s stock was trading at C$0.20 on January 1st, 2024. Since then, HUMDF stock has increased by 0.0% and is now trading at C$0.20.
View the best growth stocks for 2024 here.
Are investors shorting Hua Medicine (Shanghai)?: Hua Medicine (Shanghai) saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 337,400 shares, a drop of 22.0% from the May 15th total of 432,400 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
View Hua Medicine (Shanghai)'s Short Interest.
How do I buy shares of Hua Medicine (Shanghai)?: Shares of HUMDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.